

Extraordinary General Meeting of Active Biotech AB

The Extraordinary General Meeting of Active Biotech was held on October 23, 2024. The following main resolutions were passed.

In accordance with the Board of Directors' proposal, it was resolved to amend the Articles of Association, whereby the limits for the company's share capital are changed to not less than SEK 1,575,000 and not more than SEK 6,300,000 and the limits for the number of shares are changed to not less than 325,000,000 and not more than 1,300,000,000.

In accordance with the Board of Directors' proposal, it was further resolved to amend the Articles of Association, whereby the limits for the company's share capital are changed to not less than SEK 4,000,000 and not more than SEK 16,000,000 and the limits for the number of shares are changed to not less than 700,000,000 and not more than 2,800,000,000. The Board of Directors shall submit these Articles of Association for registration with the Swedish Companies Registration Office only if it is deemed reasonable in relation to the total number of shares and the share capital in the company following completion of the rights issue and over-allotment option per the below.

It was further resolved to approve the Board of Directors' resolution on a rights issue of shares. Through the rights issue, not more than 723,626,284 new shares are issued. The subscription price in the rights issue is SEK 0.05 per share. The record date for the right to participate in the rights issue is October 28, 2024. Subscription for the new shares shall be made during the period October 30 – November 13, 2024. Last day of trading in the company's share including the right to participate in the rights issue is October 24, 2024. For further details and information on the background to and reasons for the rights issue, refer to the company's press releases on 23 September 2024 and October 2, 2024.

In accordance with the Board's proposal, the Meeting finally resolved to authorize the Board to, for a period that does not extend past the date of the next Annual General Meeting, without pre-emptive rights for the shareholders, to resolve on the issue of new shares. It shall also be possible to make such an issue resolution stipulating in-kind payment, the right to offset debt or other conditions. The number of shares issued based on the authorization may correspond to up to 20 percent of the maximum number of shares that is issued in the rights issue mentioned above. Upon exercise of the authorization, the subscription price per share shall correspond to the subscription price in the new issue mentioned above. The purpose of the authorization is to, if needed, expand the rights issue by way of a so called over subscription option.

For further information, please contact:

Helén Tuvešson, *CEO*, +46 46 19 21 56, helen.tuvešson@activebiotech.com
Hans Kolam, *CFO*, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies has been initiated. Also ongoing is a clinical Phase Ib/IIa study in multiple myeloma. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation is ongoing to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

Attachments

Extraordinary General Meeting of Active Biotech AB